The treatment patterns, efficacy, and safety of nab®-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis

Table 6 OS and TNTD among nab-paclitaxel initiators by line of therapy and treatment schedule^a,b

Variable	Total No.	OS			TNTD
Variable	Total No.	Events	Median, mo	95 % CI	Events	Median, mo	95 % CI
Overall	605^c	274	18.1	(16.7–20.8)	452	6.4	(5.8–6.8)
Weekly	428	191	18.6	(16.1–21.6)	316	6.5	(5.8–7.1)
q3w	177	83	17.4	(14.0–21.7)	136	6.0	(5.0–7.1)
First line	152	60	23.0	(19.0–37.2)	115	7.1	(6.2–9.2)
Weekly	114	49	21.6	(18.0–29.3)	85	7.4	(6.2–10.5)
q3w^d	38	11	>22.7	–	30	6.6	(4.5–10.5)
Second line	193	86	19.4	(14.4–22.6)	138	6.9	(5.7–8.6)
Weekly	134	55	19.8	(14.4–23.8)	94	6.9	(5.7–8.8)
q3w	59	31	17.4	(12.0–26.1)	44	6.9	(5.0–9.9)
Third or later line	260	128	15.3	(12.8–17.0)	199	5.5	(4.9–6.2)
Weekly	180	87	15.9	(12.9–18.1)	137	5.8	(4.9–6.5)
q3w	80	41	13.5	(8.9–17.4)	62	5.0	(4.0–6.4)

OS overall survival, q3w every 3 weeks, TNTD time to next therapy or death
^aData are from the Optum Research Database, January 1, 2005 to September 30, 2012
^bFollow-up time was calculated from index date until disenrollment from the health plan, death (or treatment discontinuation), or the end of the study period (September 30, 2012)
^c59 patients (20 in first line, 18 in second line, and 21 in third or later line) could not be classified into a weekly or every 3 weeks treatment schedule
^dThe 95 % CI of median survival time is missing because more than half of the subjects survived during the study period

ISSN: 1471-2407